In 2009, Bendalis GmbH entered into a cooperation agreement with Eusa Pharma, a pharmaceutical company operating in the USA and Europe, for the distribution of Caphosol®.
Since the beginning of 2011, a co-promotion agreement has been in place with Riemser Arzneimittel AG for Aloxi® (Palonosetron), an innovative 5HT3 receptor antagonist for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV).